MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology

被引：10

作者：

Mach, N. ^{[1
]}

Vernet, R. ^{[1
]}

Belkouch, M-C. ^{[1
]}

Luy, P. ^{[1
]}

Ancrenaz, V. ^{[1
]}

Teta, P. ^{[1
]}

Blazek, N. ^{[1
]}

Grandjean, N. ^{[1
]}

Wasem, J. ^{[1
]}

Grogg, J. ^{[2
]}

Perez, T. ^{[2
]}

Migliorini, D. ^{[1
]}

机构：

[1] HUG, Oncol, Geneva, Switzerland

[2] MaxiVAX SA, Clin Operat, Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw378.12

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1058P

引用

页数：1

共 50 条

[21] Development of a high-throughput cell-based assay for 11β-hydroxysteroid dehydrogenase type 1 using BacMam technology
Wang, Da-Yuan
Lu, Quinn
Walsh, Stacey L.
Payne, Lisa
Modha, Sundip S.
Scott, Martin J.
Sweitzer, Thomas D.
Ames, Robert S.
Krosky, Daniel J.
Li, Hu
MOLECULAR BIOTECHNOLOGY, 2008, 39 (02) : 127 - 134
[22] NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+B CELL MALIGNANCIES
Rotolo, A.
Dubois, O.
Goudevenou, K.
Petevi, K.
Cheung, G. W.
Pule, M.
Maher, J.
Karadimitris, A.
HAEMATOLOGICA, 2017, 102 : 245 - 246
[23] Imbalance in VEGF-A/sFLT-1 Enables Malignant Ascites to Resist Dendritic Cell-based Immunotherapy
Sugiyama, M.
Yonemitsu, Y.
Kakeji, Y.
Saeki, H.
Oki, E.
Emi, Y.
Morita, M.
Morodomi, Y.
Hasegawa, M.
Maehara, Y.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S128 - S128
[24] Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors
Fernandez, E.
Vernet, R.
Charrier, E.
Migliorini, D. M.
Urwyler, M.
Belkouch, M-C.
Von Rohr, O.
Saingier, V.
Ancrenaz, V.
Grandjean, N.
Lafferma, E.
Lavalliere, E.
Rubin, O.
Villard, J.
Grogg, J. N.
Mach, N.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S891 - S891
[25] Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy
Hambach, Lothar
Ling, Kam-Wing
Pool, Jos
Aghai, Zohara
Blokland, Els
Tanke, Hans J.
Bruijn, Jan A.
Halfwerk, Hans
Van Boven, Hester
Wieles, Brigitte
Goulmy, Els
BLOOD, 2009, 113 (12) : 2715 - 2722
[26] CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
King, Lisa A.
Lameris, Roeland
de Gruijl, Tanja D.
van der Vliet, Hans J.
FRONTIERS IN IMMUNOLOGY, 2018, 9
[27] PHASE I/II OF CLINICAL STUDY OF PROSTATE CANCER IMMUNOTHERAPY USING DENDRITIC CELL VACCINATION STRATEGY - FIRST RESULTS
Minarik, I
Horvath, R.
Podrazil, M.
Hromadkova, H.
Dusek, P.
Jarolim, L.
Babjuk, M.
Bartunkova, J.
EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 629 - 629
[28] Final Results of a Phase II Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients
Chen, Y.
Zhu, Z.
Zhao, W.
Li, L.
Liu, Q.
Zhang, J.
Jiang, L.
Ai, D.
Zhang, Z.
Zhao, K.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S131 - S132
[29] Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients
Kreutz, Fernando T.
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[30] Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection
Cynthia L. Gay
Joann D. Kuruc
Shane D. Falcinelli
Joanna A. Warren
Sarah A. Reifeis
Jennifer L. Kirchherr
Katherine S. James
Morgan G. Dewey
Alyson Helms
Brigitte Allard
Erin Stuelke
Alicia Gamble
Ana Plachco
Robert J. Gorelick
Joseph J. Eron
Michael Hudgens
Carolina Garrido
Nilu Goonetilleke
Mark A. DeBenedette
Irina Y. Tcherepanova
Charles A. Nicolette
Nancie M. Archin
David M. Margolis
Scientific Reports, 10

← 1 2 3 4 5 →